Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
- PMID: 31292683
- PMCID: PMC6682847
- DOI: 10.1007/s00280-019-03890-7
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Abstract
The article "Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer" written by Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin was originally published electronically on the publisher's internet portal (currently SpringerLink) on 3rd May 2019 without open access.
Erratum for
-
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer.Cancer Chemother Pharmacol. 2019 Jul;84(1):83-92. doi: 10.1007/s00280-019-03850-1. Epub 2019 May 3. Cancer Chemother Pharmacol. 2019. PMID: 31053945 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
